This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 4 for:    VeroScience
Previous Study | Return to List | Next Study

Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
VeroScience
ClinicalTrials.gov Identifier:
NCT02078440
First received: January 23, 2014
Last updated: August 26, 2016
Last verified: August 2016
  Purpose

The objective of this study is to evaluate the relative bioavailability, and the rate and extent of absorption of bromocriptine in male and female children and adolescent Type 2 Diabetes Mellitus patients, aged 10 to less than 18, under fed conditions.

It is undetermined if the pharmacokinetic profile of bromocriptine-QR in type 2 diabetes children aged 10- to less than 18 years differs appreciably from that in healthy adults. Bromocriptine is extensively metabolized by the liver (namely CYP3A4). Studies in children have demonstrated little difference in clearance among children over 10 years of age compared to adults (Blanco et al, 2000). However, differences in blood volumes or other factors may impart differences that could affect the pharmacokinetic properties of bromocriptine-QR. Therefore, this study will assess the pharmacokinetics in children aged 10-to less than 18 years who have type 2 diabetes. After describing the profile of bromocriptine-quick release in this patient population, a follow on study will be conducted to evaluate its safety and efficacy in treating children and adolescents who have type 2 diabetes.

The pharmacokinetic profile of bromocriptine will be determined following the administration of a single, weight-adjusted dose of CYCLOSET (bromocriptine mesylate) tablets. The study will be a single period, bioavailability study in 30 patients. The study duration will be 3 days.


Condition Intervention Phase
Type 2 Diabetes Drug: Bromocriptine mesylate Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Single Dose Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets Following Administration of a Weight-Adjusted Dose in Male and Female Children and Adolescent Type 2 Diabetes Mellitus Subjects VS-PEDS BA-2010-V4

Resource links provided by NLM:


Further study details as provided by VeroScience:

Primary Outcome Measures:
  • Pharmacokinetics [ Time Frame: Thirty-six hours ]
    The pharmacokinetic parameters of interest will be Cmax, AUCT and AUC∞ and Tmax. Other parameters including AUCT/∞, Kel, T½el,CL/F, and Vd, will be provided for information purposes.


Enrollment: 18
Study Start Date: January 2014
Study Completion Date: June 2016
Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Bromocriptine mesylate (Cycloset)
Bromocriptine mesylate (Cycloset)
Drug: Bromocriptine mesylate
Cycloset (bromocriptine mesylate quick release) 0.8 mg tablets, weight adjusted 1.6 mg- 4.8 mg
Other Names:
  • Cycloset
  • Bromocriptine-QR
  • BQR

Detailed Description:

The study is a multi-center, single dose, open-label, 1-period design. Thirty (30) patients will be enrolled in the study and at least twenty-four (24) patients are expected to complete the study.

Male and female patients with confirmed Type 2 Diabetes, non-or ex-smokers, aged 10 to less than 18 years will be selected according to the inclusion and exclusion criteria.

Patients will be admitted to the clinical site at least 10 hours prior to drug administration which will occur within 2 hours of waking on the morning of Day 2.

Ondansetron hydrochloride will be administered orally, approximately 6 hours before the dosing time of Cycloset (bromocriptine mesylate). Subjects weighing 50 to 60 kg will receive 6mg ondansetron hydrochloride (liquid 7.5 ml) and subjects weighing ≥60 kg will receive ondansetron hydrochloride 8 mg (liquid 10 ml).

A single, weight-adjusted dose of CYCLOSET (bromocriptine mesylate), of approximately 0.048 mg/kg, will be administered orally with 240 mL of water in the morning, after a 10-hour overnight fast, and thirty minutes after the start of a standardized breakfast that meets American Diabetes Association diet recommendations.

On day 2, after a supervised overnight fast, the patients will be awakened, vital signs (blood pressure, pulse rate and body temperature) will be measured and the first blood sample (T= 0) will be collected.

Seventeen (17) blood samples will be collected for pharmacokinetic sampling at 0.25, 0.50, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24 and 36 hours post drug administration.

Finger sticks for blood glucose levels will be obtained every hour for the first 4 hours following administration of bromocriptine mesylate, and then additionally as deemed necessary by the study physician.

Safety will be evaluated through the assessment of adverse events and laboratory tests and vital signs.

  Eligibility

Ages Eligible for Study:   10 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Availability for entire study and willingness to adhere to protocol requirements as evidenced by (ICF) duly read, signed and dated by the patient and responsible parent or guardian
  • Positive diagnosis of T2DM according to ADA criteria. There is no requirement for time since diagnosis as long as ADA guidelines have been followed.
  • Aged at least 10 years but less than 18 years at time of enrollment
  • BMI greater than 80th percentile for age and sex and body weight equal to or greater than 50 kg
  • Clinical laboratory values within the laboratory's stated normal range - if not within this range, they must be without any clinical significance
  • Healthy according to the medical history, laboratory results and physical examination
  • Non- or ex-smokers (defined as someone who completely stopped smoking for at least 30 days before day 1 of this study).

Exclusion Criteria:

  • Evidence to indicate a diagnosis of Type 1 diabetes
  • Body weight less than 50 kilograms
  • Systolic blood pressure lower than 115mmHg or diastolic blood pressure lower than 68 mmHg
  • Significant history of hypersensitivity to bromocriptine mesylate, ondansetron, other ergot alkaloids or any related products, including excipients of the formulation as well as severe hypersensitivity reactions (like angioedema) to any drugs
  • Presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects
  • Serum aspartate aminotransferase (AST) greater than 3X ULN, and/or serum alanine aminotransferase (ALT) greater than 3X ULN, and/or serum total bilirubin greater than 2.0 mg/dL.
  • Calculated glomerular filtration rate less than 80 mL/min based on the Schwartz Formula
  • Presence or history of uncontrolled hypertension: systolic pressure greater than 145 mmHg and/or diastolic pressure greater than 95 mmHg, hypertensive disorders of pregnancy, hypertension post-partum and in the puerperium
  • History of surgery that may affect drug bioavailability, including but not limited to cholecystectomy
  • Presence of significant cardiovascular, pulmonary, hematologic, neurologic, psychiatric, endocrine, immunologic or dermatologic disease
  • Symptoms and/or history of serious psychiatric or psychotic disorders
  • Presence of significant heart disease or disorder according to ECG
  • Presence of malignancy, particularly pituitary gland malignancy and prolactinoma
  • Presence or history of migraine headache or syncope
  • Pregnant according to a positive serum pregnancy test or lactating
  • Females less then four months post-partum
  • Current history of illicit drug dependency, use or alcohol abuse (greater than 3 units of alcohol per day, intake of excessive alcohol, acute or chronic).
  • Use of drugs for the treatment of ADD and ADHD
  • Inhaled corticosteroid use other than as a rescue treatment in case of asthma attack. Use of oral glucocorticoids. Use of oral steroids within the 60 days prior to study entry.
  • Any clinically significant illness in the previous 28 days before day 1 of this study
  • Use of any cytochrome P450 (CYP) 3A4 enzyme-modifying drugs, including strong inhibitors of CYP 3A4 enzymes and strong inducers of CYP3A4 enzymes (such as barbiturates, carbamazepine, phenytoin and rifampin), in the previous 28 days before Day 1 of this study
  • Participation in another clinical trial or donation of 50 mL or more of blood in the previous 42 days before day 1 of this study
  • Donation of 500 mL or more of blood in the previous 56 days before Day 1 of this study, as well as donation in excess of 900 mL of blood over the previous 20 weeks
  • Positive urine screening of drugs of abuse
  • Positive results to HIV, HBsAg or anti-HCV tests
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02078440

Locations
United States, Arizona
Hope Research Institute, Llc
Phoenix, Arizona, United States, 85018
United States, Connecticut
Yale Center for Clinical Investigation
New Haven, Connecticut, United States, 06511
United States, Florida
Columbus Clinical Services LLC
Miami, Florida, United States, 33165
United States, Missouri
The Children's Mercy Hospital
Kansas City, Missouri, United States, 64108
United States, Pennsylvania
Children's Hosptial of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
VeroScience
Investigators
Study Director: Bindu Chamarthi, MD MMSc VeroScience
  More Information

Responsible Party: VeroScience
ClinicalTrials.gov Identifier: NCT02078440     History of Changes
Other Study ID Numbers: VS-PEDS BA-2010
Study First Received: January 23, 2014
Last Updated: August 26, 2016

Keywords provided by VeroScience:
Type 2 Diabetes
Children
Adolescents
Bioavailability
Cycloset
Bromocriptine Mesylate

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Bromocriptine
Antiparkinson Agents
Anti-Dyskinesia Agents
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 21, 2017